Blackhill Capital Inc. Sells 60,000 Shares of Pfizer Inc. (NYSE:PFE)

Blackhill Capital Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 16.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 300,644 shares of the biopharmaceutical company’s stock after selling 60,000 shares during the period. Pfizer makes up about 2.0% of Blackhill Capital Inc.’s investment portfolio, making the stock its 15th largest position. Blackhill Capital Inc.’s holdings in Pfizer were worth $9,813,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Reik & CO. LLC increased its position in Pfizer by 1.4% during the first quarter. Reik & CO. LLC now owns 19,160 shares of the biopharmaceutical company’s stock valued at $625,000 after acquiring an additional 265 shares during the last quarter. Prospera Financial Services Inc increased its position in Pfizer by 0.5% during the fourth quarter. Prospera Financial Services Inc now owns 51,834 shares of the biopharmaceutical company’s stock valued at $2,031,000 after acquiring an additional 274 shares during the last quarter. Windsor Capital Management LLC grew its holdings in shares of Pfizer by 1.6% in the first quarter. Windsor Capital Management LLC now owns 17,991 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 276 shares during the last quarter. GYL Financial Synergies LLC grew its holdings in shares of Pfizer by 0.9% in the first quarter. GYL Financial Synergies LLC now owns 30,718 shares of the biopharmaceutical company’s stock worth $1,003,000 after purchasing an additional 283 shares during the last quarter. Finally, Gilbert & Cook Inc. grew its holdings in shares of Pfizer by 3.0% in the first quarter. Gilbert & Cook Inc. now owns 9,794 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 285 shares during the last quarter. Institutional investors and hedge funds own 70.28% of the company’s stock.

In other news, major shareholder Pfizer Inc acquired 312,500 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Douglas M. Lankler sold 65,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total transaction of $2,460,250.00. Following the sale, the executive vice president now directly owns 135,375 shares in the company, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by corporate insiders.

PFE has been the topic of a number of research analyst reports. Standpoint Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Mizuho restated a “buy” rating and issued a $42.00 price target on shares of Pfizer in a report on Monday, May 18th. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Thursday, March 19th. JPMorgan Chase & Co. cut their price target on shares of Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday. Finally, Barclays upped their price target on shares of Pfizer from $36.00 to $37.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 29th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $41.19.

Shares of PFE stock traded down $2.91 during mid-day trading on Monday, hitting $35.29. 44,264,935 shares of the stock traded hands, compared to its average volume of 21,453,034. The stock has a market cap of $212.14 billion, a P/E ratio of 12.51, a P/E/G ratio of 2.79 and a beta of 0.70. The stock’s fifty day moving average is $37.10 and its two-hundred day moving average is $36.82. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.56. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.02 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.71 by $0.09. The firm had revenue of $12.03 billion during the quarter, compared to analyst estimates of $11.38 billion. Pfizer had a net margin of 31.17% and a return on equity of 25.76%. Pfizer’s revenue was down 8.3% on a year-over-year basis. During the same period last year, the firm posted $0.85 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 8th will be issued a $0.38 dividend. The ex-dividend date is Thursday, May 7th. This represents a $1.52 annualized dividend and a yield of 4.31%. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Straddles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.